Prognosis of Resected Non-small Cell Lung Cancer with Ipsilateral Pulmonary Metastasis

Üçvet, Ahmet; Yazgan, Serkan; Gürsoy, Soner; Samancılar, Özgür

doi:10.1055/s-0038-1667169

Cited by 6 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5-year OS of 56.1% for T3-Add patients in the current study seems to be a little higher than approximately 47% in the IASLC study, 9 but the survival was comparable with 52.9–55.0% in previous studies. 7,16,17 The 5-year OS for T4-Add patients was 43.4% in our study, which was comparable to nearly 40% in the IASLC study and 37.2% of Ucvet and his colleagues’ study 9,18…”

Section: Resultssupporting

confidence: 80%

“… 8 , 16 , 31 Only in Ucvet and his colleagues’ study, T4-add patients with two or more nodules were reported to have a significantly worse prognosis ( p = 0.01) but the sample size of this study was relatively low ( N = 27). 18 In the current study, there were 25.5% (37/145) and 16.7% (29/174) patients with two or more additional nodules in the T3-Add and T4-Add patients, respectively. And the number of additional nodules did not show a significant effect on prognosis of T3-Add patients (two or more nodules versus one nodule, HR, 1.153, 95% CI, 0.694–1.918, p = 0.582) and T4-Add patients (two or more nodules versus one nodule, HR, 1.230, 95% CI, 0.758–1.997, p = 0.402).…”

Section: Discussionmentioning

confidence: 42%

“…The 5-year OS for T4-Add patients of 43.4% in the present study was comparable to approximately 40.0% of T4-Add patients in several previous studies. 9 , 18 , 27 Similar to the results of the current study, in IASLC database, T4-Add patients were also reported to have a similar prognosis with all T3 patients, T3 patients diagnosed by descriptors other than additional nodule(s), and T4 patients diagnosed by descriptors other than additional nodule(s) (deaths/number of patients: T4-Add, 51/102, 50%; T3, 1693/3263, 51.8%; T3-other descriptors, 52.3%; and T4-other descriptors, 113/206, 54.8%). 9 However, no further validation of these patients with metastases in ipsilateral different lobe stratified by tumor size or histology type was conducted in IASLC database.…”

Section: Discussionmentioning

confidence: 99%

“…The 5-year OS for T4-Add patients of 43.4% in the present study was comparable to approximately 40.0% of T4-Add patients in several previous studies. 9,18,27 ). 9 However, no further validation of these patients with metastases in ipsilateral different lobe stratified by tumor size or histology type was conducted in IASLC database.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Reconsidering T component of cancer staging for T3/T4 non-small-cell lung cancer with additional nodule

Wang

et al. 2022

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: Non-small-cell lung cancer (NSCLC) with additional nodule(s) located in the same lobe or ipsilateral different lobe were designated as T3 and T4, respectively, which was merely defined by anatomical location of additional nodule(s), regardless of other prognostic factors. Methods: A total of 4711 patients with T1-4, N0-2, M0 NSCLC undergoing complete resection were identified between 2009 and 2014, including 145 patients with additional nodule(s) in the same lobe (T3-Add) and 174 patients with additional tumor nodule(s) in ipsilateral different lobe (T4-Add). Overall survival (OS) was compared using multivariable Cox regression models and propensity score matching analysis (PSM). Results: T3-Add patients [T3-Add versus T3, hazard ratio (HR), 0.695; 95% confidence interval (CI), 0.528–0.915; p = 0.009] and comparable OS with T2b patients through multivariable Cox analysis, and further validated by PSM. T4-Add patients carried a wide spectrum of prognosis, and the largest diameter of single tumor was screened out as the most effective indicator for distinguishing prognosis. T4-Add (⩽3 cm) patients had better OS than T4 patients [T4-Add (⩽3 cm) versus T4, HR, 0.629; 95% CI, 0.455–0.869; p = 0.005] and comparable OS with T3 patients. And T4-Add (>3 cm) patients had comparable OS with T4 patients. Conclusion: NSCLC patients with additional nodule(s) in the same lobe and ipsilateral different lobe (maximum tumor diameter ⩽ 3 cm) should be further validated and considered restaging as T2b and T3 in the forthcoming 9th tumor, node, and metastasis staging system.

show abstract

Section: Resultssupporting

confidence: 80%

Section: Discussionmentioning

confidence: 42%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Reconsidering T component of cancer staging for T3/T4 non-small-cell lung cancer with additional nodule

Wang

et al. 2022

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…Lung adenocarcinoma (LUAD) is the most common histological type of NSCLC. Despite significant progress in lung adenocarcinoma therapeutic methods, including surgical treatment, target therapy, and early cancer detection, the overall LUAD survival rate remains low [ 3 ]. Currently, cytology screening and imaging examination are sensitive cancer screening tools, but they are not effective for the early detection of lung adenocarcinoma [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Potentiated lung adenocarcinoma (LUAD) cell growth, migration and invasion by lncRNA DARS-AS1 via miR-188-5p/ KLF12 axis

Liu

Liang

et al. 2021

Aging

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is the most common histological type of non-small cell lung cancer (NSCLC). Due to the nonspecific early symptoms, the majority of the diagnosed LUAD patients are in the middle and late stages, with multiple metastases, and have missed the optimal period for treatment. Current studies have reported lncRNA DARS-AS1 as a cancer-promoting gene that expedites tumorigenesis. This is the first study demonstrating that DARS-AS1 is involved in the mediating process of LUAD. Cell functional experiments revealed that lncRNA DARS-AS1 participated in enhancing LUAD proliferation, invasion, and migration by inhibiting miR-188-5p. The investigation on DARS-AS1/miR-188-5p led to the discovery of KLF12 as a downstream target of miR-188-5p, and the regulatory pathway was established as DARS-AS1/miR-188-5p/KLF12. According to western blot results, DARS-AS1 promoted LUAD cell growth, migration, and invasion via stimulation of the PI3K/AKT pathway, activating the EMT process, and up-regulating the CyclinD1 and Bcl-2 proteins. This was the first report on the DARS-AS1/miR-188-5p/KLF12 axis and offered a novel strategy for early diagnosis, a new therapeutic method, and an improved prognosis for LUAD.

show abstract

Comprehensive analysis of m6A modification patterns and m6A‐related lncRNAs as potential biomarkers in lung adenocarcinoma

Wang,

Gu,

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

BackgroundN6‐methyladenosine (m6A) methylation is considered to induce tumor cell proliferation, migration, and apoptosis. Understanding the mechanism of m6A‐related lncRNAs in the development of lung adenocarcinoma (LUAD) may help predict prognosis.Methodsm6A‐related lncRNAs related to lung cancer were identified and combined with the MeRIP‐Seq dataset. The consensus clustering method was utilized to divide LUAD patients, and prognostic model was constructed using the Lasso Cox algorithm. The cluster profiler package was used for gene ontology and KEGG enrichment. The proportion of immune infiltration was estimated using the CIBERSORT algorithm. The decision tree was constructed by the rpart package, and nomograms were built by the rms package. The Connectivity Map database was analyzed for the therapeutic effects of small molecule drugs for LUAD. In addition, qPCR, colony formation and transwell assays were performed to validate functions of m6A‐associated lncRNAs.ResultsNineteen m6A‐modified lncRNAs in LUAD were identified. LUAD patients were divided into two categories based on the expression of 19 m6A‐related lncRNAs. Cluster 2 patients had better antigen production and expression, while naive B cells, plasma cells, and activated NK cells were lower in cluster 1. Nine m6A‐related lncRNAs were selected to establish a risk model for evaluating the prognosis of LUAD patients. The high‐risk group had higher tumor mutational burden and lower TIDE scores with more gamma delta T cells and neutrophils. Nomograms showed that the prognostic model had predominant predictive ability for LUAD patients based on the risk score analyzed by the decision tree model. Benzo(a)pyrene and neurodazine might improve the prognosis of LUAD patients. The qRT‐PCR results confirmed the reliability of the analytical results.ConclusionThe establishment of a prognostic model of m6A‐related lncRNAs can independently predict overall survival in LUAD and may help to develop personalized immunotherapy strategies.

show abstract

Prognosis of Resected Non-small Cell Lung Cancer with Ipsilateral Pulmonary Metastasis

Abstract: There was no significant difference in survival between T3 and T4 patients. Among surgically treated patients due to NSCLC, poor prognostic factors were advanced age for the patients with PM, nodule size and AC for T3 patients, and the number of nodules for T4 patients.

Cited by 6 publications

References 20 publications

Reconsidering T component of cancer staging for T3/T4 non-small-cell lung cancer with additional nodule

Reconsidering T component of cancer staging for T3/T4 non-small-cell lung cancer with additional nodule

Potentiated lung adenocarcinoma (LUAD) cell growth, migration and invasion by lncRNA DARS-AS1 via miR-188-5p/ KLF12 axis

Comprehensive analysis of m6A modification patterns and m6A‐related lncRNAs as potential biomarkers in lung adenocarcinoma

Contact Info

Product

Resources

About